Not surprisingly, recent clinical trials targeting key mediators of this pathway (WEEI, ATR, CHK1), in combination with classical chemotherapy aiming to induce catastrophic DNA damage, are starting to show promising results in cancer treatment, including PCa [20] (https://clinicaltrials.gov/ct2/show/NCT03787680). The gene discussed is ATR; the disease is posterior cortical atrophy.